Pharmaceutical

Basilea buys Spexis’ preclinical antibiotics programme for $2.3m

The acquired programme consists of antibiotics against gram-negative bacteria, including multidrug-resistant strains.

Jan 15, 2024 - 18:00
Basilea buys Spexis’ preclinical antibiotics programme for $2.3m
The acquired programme consists of antibiotics against gram-negative bacteria, including multidrug-resistant strains.
Read the original article

Tags:

Previous Article

MSD’s Keytruda wins expanded FDA combo approval in cervical cancer

Next Article

PCM Trials acquires Netherlands-based Clinical Trial Service, becoming the most ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opioid cravings were reduced by anti-obesity drug in small study

Opioid cravings were reduced by anti-obesity drug in sm...

Feb 17, 2024

STAT+: Medical marijuana companies are using pharma’s sales tactics with little of the same scrutiny

STAT+: Medical marijuana companies are using pharma’s s...

Dec 21, 2023

US FDA approves Ironwood Pharmaceuticals’ LINZESS

US FDA approves Ironwood Pharmaceuticals’ LINZESS

Jun 13, 2023